Related Experiment Video
Updated: Jun 9, 2026
06:36
Improved Enzyme Protection Assay to Study Staphylococcus aureus Internalization and Intracellular Efficacy of Antimicrobial Compounds
Published on: September 8, 2021
Dabigatran inhibits Staphylococcus aureus coagulase activity
Thomas Vanassche1, Jan Verhaegen, Willy E Peetermans
1Center for Molecular and Vascular Biology, University of Leuven, B-3000 Leuven, Belgium. thomas.vanassche@med.kuleuven.be
Journal of Clinical Microbiology
|September 3, 2010
Summary
Staphylocoagulase activates prothrombin to clot plasma, identifying Staphylococcus aureus. While dabigatran inhibits this, clinical dabigatran etexilate use should not affect coagulase testing.
Area of Science:
- Microbiology
- Hematology
- Clinical Diagnostics
Background:
- Staphylococcus aureus identification relies on staphylocoagulase-mediated plasma clotting.
- Coagulase-negative staphylococci lack this diagnostic capability.
Purpose of the Study:
- To evaluate the impact of dabigatran etexilate on staphylocoagulase activity.
- To determine if dabigatran etexilate interferes with direct tube coagulase testing.
Main Methods:
- In vitro assessment of staphylocoagulase activity in the presence of dabigatran.
- Analysis of direct tube coagulase test results with clinical dabigatran etexilate concentrations.
Main Results:
- Direct thrombin inhibitor dabigatran demonstrated inhibition of staphylocoagulase.
- Clinical concentrations of dabigatran etexilate did not interfere with direct tube coagulase testing.
Conclusions:
- Staphylocoagulase remains a reliable diagnostic marker for Staphylococcus aureus.
- Clinical use of dabigatran etexilate is unlikely to compromise standard coagulase testing.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:29Staphylococcal Skin Infections
Staphylococcus aureus is a Gram-positive coccus that resides harmlessly on the skin and mucous membranes of healthy individuals. When the skin barrier is breached, it can shift from a commensal to an opportunistic pathogen. This transition is facilitated by surface adhesins, such as clumping factor B and S. aureus surface protein G (SasG), which bind to structural proteins, including loricrin and cytokeratin, in the damaged epidermis. Protein A, another key factor, binds the Fc region of...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:25Clinical Significance of Antibiotic Resistance
Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...